BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.2%

Neg 0% Neu 88.2% Pos 0%

BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.

Comments

No comments yet. Be the first!